TNF and COVID-19: According to recent evidence, Nakase et al. analyzed Japanese IBD patients with COVID-19 and reported that immunosuppressive therapies other than corticosteroids (including thiopurines and anti-TNF-α agents) are associated with a relatively low risk of severe COVID-19 infection [18].